Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43843   clinical trials with a EudraCT protocol, of which   7282   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-000287-42
    Sponsor's Protocol Code Number:I15015
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2021-01-05
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2016-000287-42
    A.3Full title of the trial
    A Multicentre Open label Phase II study of Daratumumab in AL Amyloidosis in patients not in VGPR or Better
    Studio multicentrico di fase 2 con Daratumumab in pazienti affetti da amiloidosi AL che non hanno ottenuto almeno una risposta parziale molto buona dopo trattamento
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Daratumumab in AL amyloidosis patients who did not obtain a very good partial response after treatment
    Daratumumab in pazienti con amiloidosi AL che non hanno ottenuto almeno una risposta parziale molto buona dopo trattamento
    A.3.2Name or abbreviated title of the trial where available
    AMYDARA
    AMYDARA
    A.4.1Sponsor's protocol code numberI15015
    A.5.4Other Identifiers
    Name:IFM 2016-02 STUDYNumber:Codice promotore
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCHU DE LIMOGES
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportSociet¿ italiana per l'amiloidosi
    B.4.2CountryItaly
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationFondazione IRCCS Policlinico San Matteo
    B.5.2Functional name of contact pointCentro per lo studio e la cura dell
    B.5.3 Address:
    B.5.3.1Street AddressP.le Golgi 19
    B.5.3.2Town/ cityPavia
    B.5.3.3Post code27100
    B.5.3.4CountryItaly
    B.5.4Telephone number0382502994
    B.5.5Fax number0382502990
    B.5.6E-mailsegreteria.amiloidosi@smatteo.pv.it
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameHuMax-CD38
    D.3.2Product code NA
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDaratumumab
    D.3.9.1CAS number 945721-28-8
    D.3.9.2Current sponsor codeNA
    D.3.9.4EV Substance CodeSUB175772
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    AL amyloidosis
    Amiloidosi AL
    E.1.1.1Medical condition in easily understood language
    Amyloidosis
    Amiloidosi
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level HLGT
    E.1.2Classification code 10035227
    E.1.2Term Plasma cell neoplasms
    E.1.2System Organ Class 10005329 - Blood and lymphatic system disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To Assess Overall Hematologic Response Rate
    (CR + VGPR) at the completion of 6 cycles of Daratumumab in patients with AL Amyloidosis not in CR or VGPR after any previous therapy
    Determinare la percentuale di pazienti con amiloidosi AL, che non hanno ottenuto almeno una
    risposta parziale molto buona (VGPR) dopo i precedenti trattamenti, che raggiungono VGPR o una risposta completa (CR) al completamento di 6 cicli di terapia con Daratumumab
    E.2.2Secondary objectives of the trial
    ¿To determine safety and tolerability of Daratumumab (type, frequency, severity, and relationship of adverse events to study treatment).
    ¿To Assess in all patients according to their disease history
    - Overall Hematologic Response Rate (CR+VGPR+PR) at the completion of 1 and 3 the cycles.
    - The Overall Hematologic Response Rate including PR at the completion of 6 cycles
    - the duration of hematologic response
    - the rate of organ response and organ improvement, according to standard criteria
    - the time to hematologic and organ response
    - the hematologic disease progression free survival (PFS) and 1-year PFS
    - the overall survival (OS) and 1-year OS
    ¿ Assess QoL using EORTC QLQ30, EQ5D-3L and Amyloidosis Symptoms Scale
    ¿ Determinare la sicurezza e la tollerabilit¿ di Daratumumab (tipo di evento avverso, frequenza,
    seriet¿, sospensione del trattamento a causa di tossicit¿, modificazione o ritardo nella dose).
    ¿ Determinare in tutti i pazienti, e in relazione alla loro storia clinica (una linea di trattamento contro
    due o pi¿ linee):
    - Tasso di risposta ematologica totale (CR+VGPR+PR) al completamento di 1 e 3 cicli
    - Tasso di risposta ematologica totale (includendo una PR) al completamento di 6 mesi di trattamento.
    - La durata della risposta ematologica.
    - Il tasso di risposta d¿organo e miglioramento della funzionalit¿ d¿organo.-o Il tempo per il raggiungimento della risposta
    ematologica e d¿organo.
    - La sopravvivenza libera da progressione ematologica (PFS) e la PFS a un anno
    - La sopravvivenza complessiva (OS) e dopo un anno
    ¿ La qualit¿ della vita (EORTC QLQ30, EQ5D 3L e scala dei sintomi dell¿amiloidosi).
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Patients must be =18 years of age
    2. Histologic diagnosis of AL amyloidosis
    3. Patients without a clear evidence of ¿ or ¿ light chains positivity of amyloid deposits by immunohistochemistry who present: 1) with peripheral neuropathy as the dominant organ involvement should have a genetic testing negative for transthyretin mutations associated with hereditary amyloidosis, 2) who present with cardiac involvement as the dominant organ involvement should have a (99m)Tc-HMDP-scintigraphy to rule out TTR amyloidosis.
    4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2
    5. Patients should have received at least one line with an alkylating agent and/or a proteasome inhibitor and dexamethasone and not be in VGPR or CR at the time of inclusion (patients who did not reach VGPR or patients who reached VGPR or better but have an hematological relapse can be included).
    6. Measurable hematologic disease: difference between involved and uninvolved FLC > 50 mg/L with an abnormal ¿/¿ ratio (with Freelite® test kits, The Binding Site)
    7. Symptomatic organ involvement (heart, kidney, liver/GI tract, peripheral nervous system)
    8. Wash-out period of at least 4 weeks from previous antitumor therapy or any investigational treatment or 5 half-lives from previous antibodies, whichever is longer
    9. Adequate bone marrow function prior to 1 drug intake (C1D1), without transfusion or growth factor support within 5 days prior to 1 drug intake, defined as:
    Absolute neutrophils = 1000/mm
    Platelets = 50000/mm
    Hemoglobin = 8.5g/dl
    10. Adequate organ function defined as:
    Serum SGOT/AST or SGPT/ALT < 3.0 X Upper Limit Of The Normal Range (ULN)
    Serum total bilirubin < 2.0 mg/dL, unless the patient has Gilbert’s syndrome where the direct bilirubin should then be < 2.0 mg/dL
    11. Women who are partners of men and with childbearing potential* must be practicing one of the following methods of birth control : subcutaneous hormonal implant, levonorgestrel releasing intra-uterine system, medroxyprogesterone acetate depot, tubal sterilization, ovulation inhibitory progesterone only pills, or sexual intercourse with a vasectomized male partner (vasectomy must be confirmed by 2 negative semen analyses). Or women will commit to absolute and continuous abstinence confirmed to her physician on a monthly basis*. Contraception will start at the beginning of therapy including dose interruptions, and for 3 months after discontinuation of Daratumumab
    12. A woman with childbearing potential must have negative serum or urine pregnancy tests at screening and within 48H prior to dosing, and remain on a highly effective method of birth control. The two methods of reliable contraception must include one highly effective method and one additional effective (barrier) method. FCBP must be referred to a qualified provider of contraceptive methods if needed.
    13. A woman of childbearing potential must remain on a highly effective method of birth control. Contraception must start prior initiating treatment with Daratumumab, during therapy, during dose interruptions and for 3 months following discontinuation of Daratumumab. Reliable contraception is indicated even where there has been a history of infertility, unless due to hysterectomy
    14. A man who has not had a vasectomy and who is sexually active with a woman of childbearing potential must agree to use a barrier method of birth control e.g. condom with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the study and for 3 months following discontinuation of Daratumumab. The exception to this restriction is that if the subject’s female partner is surgically sterile
    15. Only patients who are informed of the investigational nature of this study and sign and give written informed consent in accordance with institutional, national and European guidelines are eligible to participate
    16. Subjects affiliated with an appropriate social security system
    - età >= 18 anni.
    -Diagnosi bioptica di amiloidosi AL.
    -Performance status (ECOG) 0, 1 o 2.
    -I pazienti devono aver ricevuto almeno una linea di trattamento con un agente alchilante e/o con un inibitore del proteasoma e desametasone e non devono avere raggiunto una risposta parziale molto buona o una risposta complete al momento dell’inclusione in questo studio (possono essere inclusi pazienti che non hanno raggiunto una VGPR o pazienti che hanno raggiunto VGPR o CR ma hanno avuto una ricaduta ematologica).
    -Malattia misurabile: differenza tra la concentrazione delle catene leggere libere coinvolte e non coinvolte >50 mg/L; con rapporto k/l al di fuori dell’intervallo di riferimento
    - Coinvolgimento d’organo sintomatico (cuore, rene, fegato/tratto gastrointestinale e sistema nervoso periferico).
    -Interruzione di almeno 4 settimane rispetto alla precedente terapia chemioterapica o di qualsiasi altro farmaco sperimentale o di 5 emivite se si tratta di terapie che comprendono anticorpi
    -Adeguata funzione midollare prima del giorno 1 del mese 1, ottenuta senza supporto nè trasfusionale nè di fattori di crescita nei 5 giorni precedenti l’inizio della terapia, definita come:
    Emoglobina =8.5 g/dL, conta dei neutrofili =1000/µL, piastrine =50000/µL.
    - Adeguata funzione d’organo:
    - SGOT/AST o SGPT/ALT < 3.0 X limite superior dell’intevallo di riferimento
    - bilirubina totale sierica < 2.0 mg/dL, a meno che il paziente sia affetto dalla Sindrome di Gilbert, in tal caso la bilirubina diretta deve essere < 2.0 mg/dL
    -Le donne in età fertile con partner devono essere d’accordo a praticare uno dei metodi contraccettivi seguenti: impianti ormonali sottocutanei, sistemi intrauterini a rilascio di levonorgestrel, sistemi depot di medrossiprogesterone acetato, sterilizzazione delle tube, pillole di solo progesterone inibitorie
    dell’ovulazione, o avere rapporti con un partner maschio vasectomizzato (la vasectomia deve essere confermata da due analisi dello sperma negative). Oppure acconsentire all’astinenza complete e continua, che deve essere confermata dal medico su base mensile. In caso di donna in età fertile la contraccezione dovrà iniziare all’inizio della terapia con Daratumumabe e continuare fino a tre mesi dopo la conclusione del trattamento.
    Gli uomini, non sottoposti a vasectomia e sessualmente attivi con partner in età fertile, dovranno accettare l’utilizzo di metodi contraccettivi ritenuti efficaci per l’intera durata dello studio e per i tre mesi successivi al termine del trattamento con Daratumumab. Devono inoltre accettare di non effettuare donazioni di sperma per l’intera durata dello studio e per i tre mesi successivi. E’ fatta eccezione per soggetti che hanno partner chirurgicamente sterile.
    -Potranno essere arruolati solo i pazienti dai quali è acquisito un consenso scritto in accordo con le linee guida istituzionali, nazionali ed europee.
    -Soggetti che sono iscritti al Sistema Sanitario Nazionale.
    E.4Principal exclusion criteria
    1. Amyloid-specific syndrome, such as carpal tunnel syndrome or skin purpura as the only evidence of disease. The finding of isolated vascular amyloid in a bone marrow biopsy specimen or in a plasmacytoma is not indicative of systemic amyloidosis 2.Isolated soft tissue involvement
    3.Presence of non-AL amyloidosis
    4.Bone marrow plasma cells >30% on bone marrow aspirate at screening
    5.Cardiac mayo stage IIIb disease. (i.e. cardio mayo stage III with NT-proBNP >= 8500 ng/L
    6.Repetitive ventricular arrhythmias on 24h Holter ECG despite anti-arrhythmic treatment, except if a pacemaker has been
    implanted.
    7.Chronic atrial fibrillation
    8.Supine systolic blood pressure <100 mmHg
    9.Subject is a woman who is pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 3 months after the last dose of any component of the treatment regimen. Or, subject is a man who plans to father a child while
    enrolled in this study or within 3 months after the last dose of any component of the treatment regimen
    10.Clinically overt multiple myeloma with lytic bone lesions
    11.Patients with uncontrolled infection or active malignancy with the exception of
    -adequately treated basal cell or squamous cell skin cancer,
    -in situ cervical cancer
    -low grade (Gleason 3+3 or less) prostate cancer or in situ breast carcinoma if surgically treated
    -adequately treated Stage I cancer from which the patient is currently in complete remission,
    -or any other cancer from which the patient has been disease-free for 3 years.
    12.Any uncontrolled or severe cardiovascular or pulmonary disease determined by the investigator including:
    - NYHA functional classification IV congestive heart failure
    - LVEF (Left Ventricular Ejection Fraction) <45%
    - Uncontrolled angina, hypertension or arrhythmia
    - Myocardial infarction in the past 6 months
    13.Subjects with psychiatric illnesses or social situations that would preclude them understanding the informed consent, study compliance or the ability to tolerate study procedures and/or study therapy
    14.Subjects with known/underlying medical conditions that, in the investigator’s opinion would make the administration of the study drug hazardous (ie: uncontrolled diabetes or uncontrolled coronary artery disease)
    15.Subjects with known chronic obstructive pulmonary disease (COPD) with a Forced Expiratory Volume in 1 second (FEV1) < 50%
    of predicted normal. Note that FEV1 testing is required for patients suspected of having COPD and subjects must be excluded if FEV1 <50% of predicted normal
    16.Subject has known moderate or severe persistent asthma within the past 2 years (see APPENDIX 8), or currently has uncontrolled asthma of any classification. (Note that subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed in the study)
    17.Previous anti-CD38 therapy
    18.Hypersensitivity to Dexamethasone that would prohibit treatment with study therapy
    19.Known positive for HIV or active hepatitis B or C
    20.Refusal to consent or protected by legal regime
    1. Sindromi amiloide-specifiche, quali sindrome del tunnel carpale o porpora cutanea, come unica
    manifestazione della malattia. La presenza di depositi di amiloide a livello delle pareti dei vasi rilevate all’analisi di una biopsia osteomidollare o in un plasmocitoma, non è indicativa di amiloidosi
    sistemica.
    2. Coinvolgimento isolato dei tessuti molli.
    3. Presenza di amiloidosi non-AL.
    4. Infiltrato plasmacellulare nel midollo osseo >30% allo screening.
    5. Interessamento cardiaco di stadio III (Mayo stage) (con NT-proBNP ³ 8500ng/L) .
    6. Presenza di aritmie ventricolari ripetitive ad un ECG dinamico secondo Holter nonostante l’utilizzo di farmaci antiaritmici.ad eccezione di pazienti con pacemaker
    7. Fibrillazione atriale cronica.
    8. Pressione sistolica arteriosa in clinostatismo <100 mmHg
    9. Pazienti in gravidanza, o in allattamento, o che stanno pianificando una gravidanza al momento
    dell’arruolamento o entro tre mesi dalla data dell’ultima somministrazione di qualsiasi componente del regime di trattamento. O pazienti di sesso maschile che pianificano di diventare padri al momento dell’arruolamento o entro tre mesi dall’ultima somministrazione di qualsiasi componente del regime di trattamento.
    10. Presenza di mieloma multiplo con lesioni ossee litiche.
    11. Pazienti con infezioni non controllate o malattie proliferative in fase attiva ad eccezione di tumori
    cutanei a cellule basali o squamose adeguatamente trattati, tumore in situ della cervice uterina, tumore della prostata di basso
    grado (Gleason 3+3 o meno) o tumore in situ del seno se trattato chirurgicamente, tumori in stadio I adeguatamente trattati e dai quali il paziente è in remissione completa o qualsiasi altra forma tumorale dalla quale il paziente è in remissione da almeno 3 anni.
    12. Pazienti con qualsiasi patologia cardiovascolare o polmonare di grado severo e non controllata determinate dal medico dello
    studio, inclusi:
    - classificazione NYHA IV insufficienza cardiaca congestiva
    - Frazione di eiezione<45%
    - angina non controllata, ipertensione o aritmie
    - infarto del miocardio negli ultimi 6 mesi
    13. Pazienti con malattie psichiatriche che potrebbero interferire con la comprensione del consenso informato, con la partecipazione e/o la compliance allo studio o la capacità di comprendere le procedure dello studio.
    14. Pazienti con patologie che a discrezione dell’investigatore, potrebbero rendere pericolosa l’assunzione del farmaco dello studio
    (es. diabete non controllato, coronaropatia non controllata).
    15. Pazienti con malattia polmonare ostruttiva cronica (COPD) con un Volume Espiratorio Forzato in 1 secondo (FEV1) < 50% del valore normale predetto. Considerare che la valutazione FEV1 è richiesta per pazienti con sospetta COPD e i pazienti devono essere esclusi qualora FEV1 sia <50% del valore normale predetto
    16. Pazienti che hanno avuto asma persistente severa o moderata negli ultimi due anni, o che presentano attualmente asma non controllata di qualsiasi classificazione. (I pazienti che presentano asma intermittente controllata o asma persistente controllata sono eligibili)
    17. Precedente terapia con farmaci anti-CD38
    18. Ipersensibilità al Desametasone tale da impedirne l’assunzione di questo farmaco durante lo studio.
    19. Positività al test dell’HIV, epatite B o C in fase attiva.
    20. Incapacità di comprendere e indisponibilità a firmare un modulo di consenso informato prima di
    avviare qualsiasi procedura dello studio.
    E.5 End points
    E.5.1Primary end point(s)
    Thee Overall Response Rate (CR+VGPR) in patients with AL Amyloidosis not in CR or VGPR after any previous therapy, using the new response criteria.
    La percentuale di pazienti con amiloidosi AL che non hanno ottenuto almeno una risposta parziale molto buona (VGPR) dopo i precedenti trattamenti, che raggiungono VGPR o una risposta completa (CR)
    E.5.1.1Timepoint(s) of evaluation of this end point
    After 6 cycles
    Dopo 6 cicli
    E.5.2Secondary end point(s)
    1. Type, frequency, severity, relationship of adverse events to study treatment and changes in vital signs, physical exams, incidence of Treatment Emergent Adverses E vents ( TEAE), Serious Adverses Events (SAE), drug discontinuation for toxicity, dose modification/delay and laboratory abnormalities will be assessed using NCI-CTCAE V4.03
    2. In all patients according to their disease history
    2.1. the overall hematologic response rate (CR + VGPR + PR) at the completion of 1 and 3 cycles
    2.2. the Overall Hematologic Response Rate including PR at the completion of 6 cycles
    2.3. the time to hematologic disease progression
    2.4. the rate of organ response and organ improvement, according to standard criteria
    2.5. the time to hematologic and organ response
    2.6. the hematologic disease progression free survival (PFS) and 1-year PFS
    2.7. the overall survival (OS) and 1-year OS
    The data used for the primary statistical analysis will be central laboratories data. Key parameters will be M-protein, serum free light chain dosage and ratio, and DIRA when applicable.
    3. QoL using EORTC QLQ30, EQ5D-3L, Amyloidosis Symptoms Scale
    1. Type, frequency, severity, relationship of adverse events to study treatment and changes in vital signs, physical exams, incidence of Treatment Emergent Adverses E vents ( TEAE), Serious Adverses Events (SAE), drug discontinuation for toxicity, dose modification/delay and laboratory abnormalities will be assessed using NCI-CTCAE V4.03
    2. In all patients according to their disease history
    2.1. the overall hematologic response rate (CR + VGPR + PR) at the completion of 1 and 3 cycles
    2.2. the Overall Hematologic Response Rate including PR at the completion of 6 cycles
    2.3. the time to hematologic disease progression
    2.4. the rate of organ response and organ improvement, according to standard criteria
    2.5. the time to hematologic and organ response
    2.6. the hematologic disease progression free survival (PFS) and 1-year PFS
    2.7. the overall survival (OS) and 1-year OS
    The data used for the primary statistical analysis will be central laboratories data. Key parameters will be M-protein, serum free light chain dosage and ratio, and DIRA when applicable.
    3. QoL using EORTC QLQ30, EQ5D-3L, Amyloidosis Symptoms Scale
    E.5.2.1Timepoint(s) of evaluation of this end point
    Safety is evaluated at the start of each cycle Responses at the completion of 1 and 3 cycles
    The Overall Hematologic Response Rate including PR at the completion of 6 cycles
    La sicurezza viene valutata all'inizio di ogni ciclo
    La risposta ematologica al completamento dei cicli 1 e 3.
    Il tasso di risposta ematologica totale al completamento dei 6 cicli
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.4.1Number of sites anticipated in Member State concerned1
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA24
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months30
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months30
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 2
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 3
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state5
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 40
    F.4.2.2In the whole clinical trial 40
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Patient will continue observation according to standard clinical practice
    Il paziente riprender¿ l'osservazione presso il Centro secondo la normale pratica clinica
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-10-18
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-06-05
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2019-09-27
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA